Open-Label Trial of Riluzole in Generalized Anxiety Disorder
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: There is a need to identify novel pharmacotherapies for anxiety disorders. The authors examined the safety and efficacy of riluzole, an antiglutamatergic agent, in adult outpatients with generalized anxiety disorder. METHOD: In an 8-week, open-label, fixed-dose study, 18 medically healthy patients with DSM-IV generalized anxiety disorder received treatment with riluzole (100 mg/day) following a 2-week drug-free period. The primary efficacy measure was the Hamilton Anxiety Rating Scale (HAM-A) score at endpoint. RESULTS: Twelve of the 15 patients who completed the trial responded positively to riluzole. At 8 weeks, eight of the 15 patients had HAM-A score indicating remission of their anxiety. The median time to response was 2.5 weeks. CONCLUSIONS: Riluzole appears to be an effective, well-tolerated, and rapidly acting anxiolytic medication for some patients with generalized anxiety disorder. Larger, placebo-controlled studies are indicated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multicenter Collaborative Panic Disorder Severity Scale
Shear, M. K., Brown, T. A., Barlow, D. H., Money, R., Sholomskas, D. E., Woods, S. W., Gorman, J. M., & Papp, L. A. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.11.1571 · Cited by 1,001
Self-citationCoplan, J. D., Mathew, S. J., Smith, E. L. P., Trost, R. C., Scharf, B. A., Martinez, J., Gorman, J. M., Monn, J. A., Schoepp, D. D., & Rosenblum, L. A. (2001) · CNS Spectrums · doi:10.1017/s1092852900002157 · Cited by 18
Self-citation
Cited by
The GABA system in anxiety and depression and its therapeutic potential
Möhler, H. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.040 · Cited by 590
The Neurobiology of Anxiety Disorders: Brain Imaging, Genetics, and Psychoneuroendocrinology
Martin, E. I., Ressler, K. J., Binder, E., & Nemeroff, C. B. (2009) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2009.05.004 · Cited by 557
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
Pittenger, C., Bloch, M. H., & Williams, K. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.006 · Cited by 426
“Open-label studies suggest efficacy in major depressive disorder, bipolar depression, and generalized anxiety (Mathew et al., 2005; Sanacora, Kendell, Fenton, Coric, & Krystal, 2004; Sanacora et al., 2007; C. A. Zarate, Jr. et al., 2004; C. A. Zarate, Jr. et al., 2005; C. A. Zarate & Manji, 2008); no controlled studie…”
BackgroundIdentifying HAM‐A cutoffs for mild, moderate, and severe generalized anxiety disorder
Matza, L. S., Morlock, R., Sexton, C., Malley, K., & Feltner, D. (2010) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.323 · Cited by 269
Metadata
- Authors
- Mathew, S. J., Amiel, J. M., Coplan, J. D., Fitterling, H. A., Sackeim, H. A., & Gorman, J. M.
- Venue
- American Journal of Psychiatry
- Published
- 2005-12-01
- Volume
- 162
- Issue
- 12
- Pages
- 2379-2381
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W1970076964
- Cited by
- 134
- References
- 2
- FWCI
- 12.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Open-Label Trial of Riluzole in Generalized Anxiety Disorder. https://app.cochat.ai/papers/10.1176/appi.ajp.162.12.2379
- The paper
- Mathew, S. J., Amiel, J. M., Coplan, J. D., Fitterling, H. A., Sackeim, H. A., & Gorman, J. M. (2005). Open-Label Trial of Riluzole in Generalized Anxiety Disorder. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.162.12.2379
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.